Patents by Inventor Jesper Valbjorn

Jesper Valbjorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATE LYOPHILISED FORMULATION
    Publication number: 20240091373
    Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.
    Type: Application
    Filed: December 13, 2022
    Publication date: March 21, 2024
    Inventors: Jesper VALBJØRN, Xiaona JING, Kelly Ann ROBY, Timothy Warren PAUL, Gregory Allan SACHA, Nathan Alan PEASE, Bodil WILLUMSEN
  • ANTIBODY-DRUG CONJUGATE LYOPHILISED FORMULATION
    Publication number: 20200246477
    Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.
    Type: Application
    Filed: January 14, 2020
    Publication date: August 6, 2020
    Inventors: Jesper VALBJØRN, Xiaona JING, Kelly Ann ROBY, Timothy Warren PAUL, Gregory Allan SACHA, Nathan Alan PEASE, Bodil WILLUMSEN
  • Lyophilized anti-tissue factor antibody-drug conjugates
    Patent number: 10617764
    Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 14, 2020
    Assignee: GENMAB A/S
    Inventors: Jesper Valbjørn, Xiaona Jing, Kelly Ann Roby, Timothy Warren Paul, Gregory Allan Sacha, Nathan Alan Pease, Bodil Willumsen
  • ANTIBODY-DRUG CONJUGATE LYOPHILISED FORMULATION
    Publication number: 20160279258
    Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.
    Type: Application
    Filed: November 21, 2014
    Publication date: September 29, 2016
    Inventors: Jesper VALBJØRN, Xiaona JING, Kelly Ann ROBY, Timothy Warren PAUL, Gregory Allan SACHA, Nathan Alan PEASE, Bodil WILLUMSEN
  • NOVEL CARBAMYLATED EPO AND METHOD FOR ITS PRODUCTION
    Publication number: 20120220757
    Abstract: The present invention discloses a method for production of novel carbamylated erythropoietin and compositions comprising the novel carbamylated erythropoietin and pharmaceutical compositions comprising this and uses thereof.
    Type: Application
    Filed: September 30, 2011
    Publication date: August 30, 2012
    Applicant: H. Lundbeck A/S
    Inventors: Søren Christensen, Lars Foldager, Jesper Valbjørn, Marianne Hallberg Thuesen, Anders H. Pedersen, Morten Munk
  • Novel carbamylated EPO and method for its production
    Publication number: 20060135754
    Abstract: The present invention discloses a method for production of novel carbamylated erythropoietin and compositions comprising the novel carbamylated erythropoietin and pharmaceutical compositions comprising this and uses thereof.
    Type: Application
    Filed: July 7, 2005
    Publication date: June 22, 2006
    Applicant: H. Lundbeck A/S
    Inventors: Soren Christensen, Lars Foldager, Jesper Valbjorn, Marianne Thuesen, Anders Pedersen, Morten Munk